» Articles » PMID: 36185615

The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors

Overview
Specialty Psychiatry
Date 2022 Oct 3
PMID 36185615
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: a)This review paper describes the state of prescribing practice in Borderline Personality Disorder (BPD), wherein medications are prescribed far more than either evidence or practice guideline would recommend. First, we describe the frequencies of medication use and polypharmacy in people with BPD.

Recent Findings: b)In subsequent sections, we elaborate two main categories of factors that lead to overmedication of people with BPD: the interpersonally mediated and the structural. We consider interpersonally mediated factors to arise from communications of patients in distress and the well-meaning efforts of their prescribers to provide relief for certain overwhelming affective states. We are particularly focused on patterns of countertransference in prescribing that are directly linked to specific aspects of BPD pathology. We consider structural factors to arise from the complexities of medical and medicolegal systems and the contemporary patterns of financing medical care; we postulate that these complexities often compel prescribers to start medications, with associated disincentives for decreasing or discontinuing those medications over time.

Summary: c)More research is needed to understand how to best use medications in BPD, for example in targeted combination with psychotherapeutic and psychosocial interventions. However, current practice often departs markedly from the evidence. We recommend the dissemination of accessible, generalist BPD-treatment models in outpatient and inpatient practice; increased early detection of BPD; and increased diagnostic disclosure. We also recommend for individual providers and systems to implement prospective treatment plans that draw from BPD-specific psychosocial models. This approach can employ tiers of interventions to minimize reactive prescribing by anticipating high affect and offering BPD patients steadily empathic evidence-supported care.

Citing Articles

Factors That Influence Prescribing in Borderline Personality Disorder: A Systematic Review.

Confue J, Maidment I, Jones S, Jones M Personal Ment Health. 2025; 19(2):e70014.

PMID: 40010400 PMC: 11864820. DOI: 10.1002/pmh.70014.


Borderline Personality Disorder: A Comprehensive Review of Current Diagnostic Practices, Treatment Modalities, and Key Controversies.

Azzam S, Almari R, Khattab K, Badr A, Balawi A, Haddad R Cureus. 2025; 16(12):e75893.

PMID: 39822482 PMC: 11738078. DOI: 10.7759/cureus.75893.


Characterizing psychopharmacological prescribing practices in a large cohort of adolescents with borderline personality disorder.

Hauryski S, Potts A, Swigart A, Babinski D, Waschbusch D, Forrest L Borderline Personal Disord Emot Dysregul. 2024; 11(1):17.

PMID: 39103898 PMC: 11302085. DOI: 10.1186/s40479-024-00262-3.


Why do patients want medication free treatment for psychosis? An explorative study on reasons for applying to medication free programs.

Reitan E, Iversen V, Riley H, Hoye A BMC Psychiatry. 2024; 24(1):127.

PMID: 38365662 PMC: 10870549. DOI: 10.1186/s12888-024-05513-9.

References
1.
Garfinkel D . Overview of current and future research and clinical directions for drug discontinuation: psychological, traditional and professional obstacles to deprescribing. Eur J Hosp Pharm. 2019; 24(1):16-20. PMC: 6451531. DOI: 10.1136/ejhpharm-2016-000959. View

2.
Timaus C, Meiser M, Bandelow B, Engel K, Paschke A, Wiltfang J . Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry. 2019; 19(1):393. PMC: 6909459. DOI: 10.1186/s12888-019-2377-z. View

3.
Kukreja S, Kalra G, Shah N, Shrivastava A . Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013; 11(1):82-99. PMC: 3653237. DOI: 10.4103/0973-1229.104497. View

4.
Hoffman P, Fruzzetti A . Advances in interventions for families with a relative with a personality disorder diagnosis. Curr Psychiatry Rep. 2007; 9(1):68-73. DOI: 10.1007/s11920-007-0012-z. View

5.
Wickizer T, Lessler D, Travis K . Controlling inpatient psychiatric utilization through managed care. Am J Psychiatry. 1996; 153(3):339-45. DOI: 10.1176/ajp.153.3.339. View